Newsroom

Sera announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market.

Sera Prognostics announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. ET.

Sera announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share

Sera announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock.

One of the Largest Studies on Preterm Birth Finds a Maternal Biomarker Test Significantly Reduces Neonatal Morbidities and Improves Neonatal Outcomes Denver, Colo. ― Preterm birth ― defined as delivery before…

Sera Prognostics announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference

Sera Prognostics announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at SMFM

Sera Prognostics will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024

Sera announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum